Familial breast cancer risk

Current Breast Cancer Reports

Volumn 5, Issue 3, 2013, Pages 170-182

  Maxwell, Kara N ^a   Domchek, Susan M ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

ATM; BRCA1; BRCA2; Breast cancer; Breast cancer susceptibility; BRIP1; Cancer predisposition syndromes; CDH1; CHEK2; Cowden syndrome; Familial breast cancer; Hereditary breast ovarian cancer syndrome; Li Fraumeni syndrome; Moderate penetrance; PALB2; PTEN; STK11; TP53

Indexed keywords

ATM PROTEIN; CHECKPOINT KINASE 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; ORAL CONTRACEPTIVE AGENT; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATINUM COMPLEX; PROTEIN KINASE LKB1; PROTEIN P53; TAMOXIFEN; UVOMORULIN;

ARTICLE; ATM GENE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CDH1 GENE; CHEK2 GENE; CHEMOPROPHYLAXIS; CHEMOSENSITIVITY; CONSERVATIVE TREATMENT; COWDEN SYNDROME; DISTANT METASTASIS; FAMILIAL CANCER; GENE; GENE MUTATION; GENE NUMBER; GENETIC RISK; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HEREDITARY DIFFUSE GASTRIC CANCER SYNDROME; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; HYSTERECTOMY; MASTECTOMY; OVARY CANCER; OVERALL SURVIVAL; PALB2 GENE; PENETRANCE; PEUTZ JEGHERS SYNDROME; PRACTICE GUIDELINE; PRIMARY TUMOR; PTEN GENE; RAD51C GENE; RAD51D GENE; SALPINGOOOPHORECTOMY; STK11 GENE; STOMACH CANCER; SYNDROME; TP53 GENE; TUMOR SUPPRESSOR GENE;

EID: 84884354859     PISSN: 19434588     EISSN: 19434596     Source Type: Journal    
DOI: 10.1007/s12609-013-0117-9     Document Type: Article

References (155)

1. Howlader N, Noone AM, Krapcho M, et al., editors. SEER Cancer Statistics Review, 1975-2009. Bethesda: National Cancer Institute; 2011.
2. Daly MB, Axilbund JE, Buys S, et al. Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw. 2010;8:562-94.
3. Foulkes WD. Inherited susceptibility to common cancers. N Engl J Med. 2008;359:2143-53.
4. Pharoah PD, Antoniou A, Bobrow M, et al. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet. 2002;31:33-6.
5. Maxwell KN, Domchek SM. Cancer treatment according to BRCA1 and BRCA2 mutations. Nat Rev Clin Oncol. 2012;9:520-8.
6. Michailidou KP, Hall A, Gonzalez-Neira, et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet. 2013;45:353-61.
7. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group. Br J Cancer. 2000;83:1301-8
8. Antoniou A, Pharoah D, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117-30. (Pubitemid 36530000)
9. Gonzalez KD, Buzin CH, Noltner KA, et al. High frequency of de novo mutations in Li-Fraumeni syndrome. J Med Genet. 2009;46:689-93.
10. Hwang SJ, Lozano G, Amos CI, Strong LC. Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. Am J Hum Genet. 2003;72:975-83. (Pubitemid 36403315)
11. Nelen MR, Kremer H, Konings IB, et al. Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations. Eur J Hum Genet. 1999;7:267-73. (Pubitemid 29213732)
12. Schrager CA, Schneider D, Gruener AC, et al. Clinical and pathological features of breast disease in Cowden's syndrome: an under recognized syndrome with an increased risk of breast cancer. Hum Pathol. 1998;29:47-53. (Pubitemid 28049545)
13. Izatt L, Greenman J, Hodgson S, et al. Identification of germline missense mutations and rare allelic variants in the ATM gene in early-onset breast cancer. Genes Chromosomes Cancer. 1999;26:286-94. (Pubitemid 29529573)
14. Meijers-Heijboer H, van den Ouweland A, Klijn J, et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet. 2002;31:55-9.
15. Rahman N, Seal S, Thompson D, et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet. 2007;39:165-7. (Pubitemid 46184346)
16. Seal S, Thompson D, Renwick A, et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet. 2006;38:1239-41. (Pubitemid 44646283)
17. Hemel D, Domchek SM. Breast cancer predisposition syndromes. Hematol Oncol Clin North Am. 2010;24:799-814.
18. Gudmundsdottir K, Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene. 2006;25:5864-74. (Pubitemid 44453442)
19. O'Donovan PJ, Livingston DM. BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Carcinogenesis. 2010;31:961-7.
20. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst. 1999;91:1310-6.
21. Begg CB, Haile RW, Borg A, et al. Variation of breast cancer risk among BRCA1/2 carriers. JAMA. 2008;299:194-201.
22. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25:1329-33. (Pubitemid 46706879)
23. • Mavaddat N, Peock S, Frost D, et al. Cancer risks for BRCA1 and BRCA2 Mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst. 2013. [Epub ahead of print]. This article describes results of a trial prospectively examining cancer risks in BRCA1 and BRCA2 carriers.
24. • Castro E, Goh C, Olmos D, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. 2013;31:1748-57. This article highlights the role of identifying prostate cancer patients with BRCA1 or BRCA2 mutations. In addition, this artical strongly supports the recommendation that male members of BRCA1/2 families should undergo early prostate cancer screening.
25. Howlett NG, Taniguchi T, Olson S, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science. 2002;297:606-9. (Pubitemid 34815345)
26. Alter BP, Rosenberg PS, Brody LC. Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. J Med Genet. 2007;44:1-9. (Pubitemid 46142832)
27. Domchek SM, Tang J, Stopfer J, et al. Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancer. Cancer Discov. 2013;3:399-405.
28. Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med. 2004;351:427-37. (Pubitemid 38988592)
29. Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57:75-89. (Pubitemid 46535708)
30. King MC, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA. 2001;286:2251-6. (Pubitemid 33063147)
31. Whittemore AS, Balise RR, Pharoah PD, et al. Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. Br J Cancer. 2004;91:1911-5. (Pubitemid 40065520)
32. Cibula D, Zikan M, Dusek L, Majek O. Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis. Expert Rev Anticancer Ther. 2011;11:1197-207.
33. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304:967-75.
34. Kurian AW, Sigal BM, Plevritis SK. Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol. 2010;28:222-31.
35. Eisen A, Lubinski J, Gronwald J, et al. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst. 2008;100:1361-7.
36. Rebbeck TR, Friebel T, Wagner T, et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2005;23:7804-10. (Pubitemid 46657377)
37. Arun B, Bayraktar S, Liu DD, et al. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol. 2011;29:3739-46.
38. Kriege M, Seynaeve C, Meijers-Heijboer H, et al. Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2009;27:3764-71.
39. Byrski T, Gronwald J, Huzarski T, et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol. 2010;28:375-9.
40. Bolton KL, Chenevix-Trench G, Goh C, et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA. 2012;307:382-90.
41. Adams SF, Marsh EB, Elmasri W, et al. A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer. Gynecol Oncol. 2011;123:486-91.
42. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361:123-34.
43. Audeh MW, Penson RT, Friedlander M, Powell B, Bell-Mcguinn KM, Scott C, et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer. J Clin Oncol. 2009;27:277s.
44. •• Kaye SB, Lubinski J, Matulonis U, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol. 2012;30:372-9. The effectiveness of PARP inhibitors in BRCA1/2 carriers indicates that identification of gene mutations leading to familial breast cancer may have important implications for treatment.
45. Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376:235-44.
46. Li FP, Fraumeni JF. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med. 1969;71:747-52.
47. Li FP, Fraumeni JF, Mulvihill Jr JJ, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res. 1988;48:5358-62.
48. Frebourg T, Barbier N, Yan YX, et al. Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome. Am J Hum Genet. 1995;56:608-15.
49. Gonzalez KD, Noltner KA, Buzin CH, et al. Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol. 2009;27:1250-6.
50. Varley JM, McGown G, Thorncroft M, et al. Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families. Cancer Res. 1997;57:3245-52. (Pubitemid 27351742)
51. Green DR, Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature. 2009;458:1127-30.
52. Birch JM, Hartley AL, Tricker KJ, et al. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res. 1994;54:1298-304. (Pubitemid 24108072)
53. Chompret A, Brugieres L, Ronsin M, et al. P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer. 2000;82:1932-7. (Pubitemid 30326453)
54. Eeles RA. Germline mutations in the TP53 gene. Cancer Surv. 1995;25:101-24. (Pubitemid 26065308)
55. Lalloo F, Varley J, Moran A, et al. BRCA1, BRCA2, and TP53 mutations in very early-onset breast cancer with associated risks to relatives. Eur J Cancer. 2006;42:1143-50.
56. Mouchawar J, Korch C, Byers T, et al. Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study. Cancer Res. 2010;70:4795-800.
57. Lee DS, Yoon SY, Looi LM, et al. Comparable frequency of BRCA1, BRCA2, and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients. Breast Cancer Res. 2012;14:R66.
58. McCuaig JM, Armel SR, Novokmet A, et al. Routine TP53 testing for breast cancer under age 30: ready for prime time? Fam Cancer. 2012;11:607-13.
59. He XF, Su J, Zhang Y, et al. Association between the p53 polymorphisms and breast cancer risk: meta-analysis based on case-control study. Breast Cancer Res Treat. 2011;130:517-29.
60. Zhang B, Beeghly-Fadiel A, Long J, Zheng W. Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. Lancet Oncol. 2011;12:477-88.
61. Varley JM, McGown G, Thorncroft M, et al. Are there low-penetrance TP53 Alleles? Evidence from childhood adrenocortical tumors. Am J Hum Genet. 1999;65:995-1006. (Pubitemid 30462956)
62. Ruijs MW, Verhoef S, Wigbout G, et al. Late-onset common cancers in a kindred with an Arg213Gln TP53 germline mutation. Fam Cancer. 2006;5:169-74. (Pubitemid 43824473)
63. • Giacomazzi J, Selistre S, Duarte J, et al. TP53 p.R337H is a conditional cancer-predisposing mutation: further evidence from a homozygous patient. BMC Cancer. 2013;13:187. The identification of an individual homozygous for a TP53 mutation suggests that hypomorphic TP53 mutations may exist.
64. Lammens CR, Aaronson NK, Wagner A, et al. Genetic testing in Li-Fraumeni syndrome: uptake and psychosocial consequences. J Clin Oncol. 2010;28:3008-14.
65. Lammens CR, Bleiker EM, Aaronson NK, et al. Regular surveillance for Li-Fraumeni Syndrome: advice, adherence, and perceived benefits. Fam Cancer. 2010;9:647-54.
66. • Mai PL, Malkin D, Garber JE, et al. Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium. Cancer Genet. 2012;205:479-87. This report highlights the critical areas of need for additional research in the management of individuals with TP53 mutations and from LFS families.
67. Monsalve J, Kapur J, Malkin D, Babyn PS. Imaging of cancer predisposition syndromes in children. Radiographics. 2011;31:263-80.
68. Henry E, Villalobos V, Million L, et al. Chest wall leiomyosarcoma after breast-conservative therapy for early-stage breast cancer in a young woman with Li-Fraumeni syndrome. J Natl Compr Canc Netw. 2012;10:939-42.
69. Salmon A, Amikam D, Sodha N, et al. Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline 'de-novo' TP53 mutation. Clin Oncol (R Coll Radiol). 2007;19:490-3. (Pubitemid 47181183)
70. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 1998;273:13375-8. (Pubitemid 28268370)
71. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275:1943-7. (Pubitemid 27148818)
72. Liaw D, Marsh DJ, Li J, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet. 1997;16:64-7. (Pubitemid 27198157)
73. Hobert JA, Eng C. PTEN hamartoma tumor syndrome: an overview. Genet Med. 2009;11:687-94.
74. Bubien V, Bonnet F, Brouste V, et al. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. J Med Genet. 2013;50:255-63.
75. • Tan MH, Mester JL, Ngeow J, et al. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res. 2012;18:400-7. This article demonstrates high lifetime risks of cancers in Cowden syndrome families.
76. Ragaz J, Coldman A. Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes. J Clin Oncol. 1998;16:2018-24. (Pubitemid 28265035)
77. Hemminki A, Markie D, Tomlinson I, et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature. 1998;391:184-7. (Pubitemid 28092478)
78. Jenne DE, Reimann H, Nezu J, et al. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet. 1998;18:38-43. (Pubitemid 28027876)
79. Hawley SA, Boudeau J, Reid JL, et al. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol. 2003;2:28.
80. Hearle N, Schumacher V, Menko FH, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res. 2006;12:3209-15. (Pubitemid 43837371)
81. • van Lier MG, Wagner A, Mathus-Vliegen EM, et al. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol. 2010;105:1258-64. This review provides extensive recommendations specifically for PJS.
82. Watabe M, Nagafuchi A, Tsukita S, Takeichi M. Induction of polarized cell-cell association and retardation of growth by activation of the E-cadherin-catenin adhesion system in a dispersed carcinoma line. J Cell Biol. 1994;127:247-56. (Pubitemid 24307671)
83. Keller G, Vogelsang H, Becker I, et al. Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. Am J Pathol. 1999;155:337-42. (Pubitemid 29370383)
84. Pharoah PD, Guilford P, Caldas C. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology. 2001;121:1348-53. (Pubitemid 33140452)
85. Schrader KA, Masciari S, Boyd N, et al. Hereditary diffuse gastric cancer: association with lobular breast cancer. Fam Cancer. 2008;7:73-82.
86. Fitzgerald RC, Hardwick R, Huntsman D, et al. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet. 2010;47:436-44.
87. Hebbard PC, Macmillan A, Huntsman D, et al. Prophylactic total gastrectomy (PTG) for hereditary diffuse gastric cancer (HDGC): the Newfoundland experience with 23 patients. Ann Surg Oncol. 2009;16:1890-5.
88. Masciari S, Larsson N, Senz J, et al. Germline E-cadherin mutations in familial lobular breast cancer. J Med Genet. 2007;44:726-31. (Pubitemid 350155461)
89. • Schrader KA, Masciari S, Boyd N, et al. Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers. J Med Genet. 2011;48:64-8. This article suggests that CDH1 mutations are likely not responsible for familial breast cancer alone and that families without gastric cancer are unlikely to carry CDH1 mutations.
90. Xie ZM, Li LS, Laquet C, et al. Germline mutations of the E-cadherin gene in families with inherited invasive lobular breast carcinoma but no diffuse gastric cancer. Cancer. 2011;117:3112-7.
91. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96:261-8. (Pubitemid 38256271)
92. Grandval P, Barouk-Simonet E, Bronner M, et al. Is the controversy on breast cancer as part of the Lynch-related tumor spectrum still open? Fam Cancer. 2012;11:681-3.
93. Dowty JG, Win AK, Buchanan DD, et al. Cancer risks for MLH1 and MSH2 mutation carriers. Hum Mutat. 2013;34:490-7.
94. Win AK, Young JP, Lindor NM, et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol. 2012;30:958-64.
95. • Win AK, Lindor NM, Jenkins MA. Risk of breast cancer in Lynch syndrome: a systematic review. Breast Cancer Res. 2013;15:R27. This article attempts to address the controversy of whether mutations in mismatch repair genes lead to increased breast cancer risk.
96. Vasen HF, Blanco I, Aktan-Collan K, et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut. 2013;62:812-23.
97. Chaturvedi P, Eng WK, Zhu Y, et al. Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene. 1999;18:4047-54. (Pubitemid 29363911)
98. Bell DW, Varley JM, Szydlo TE, et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science. 1999;286:2528-31. (Pubitemid 30026346)
99. Weischer M, Bojesen SE, Tybjaerg-Hansen A, et al. Increased risk of breast cancer associated with CHEK2*1100delC. J Clin Oncol. 2007;25:57-63. (Pubitemid 350003051)
100. Weischer M, Nordestgaard BG, Pharoah P, et al. CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer. J Clin Oncol. 2012;30:4308-16.
101. Adank MA, Jonker MA, Kluijt I, et al. CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women. J Med Genet. 2011;48:860-3.
102. •• Cybulski C, Wokolorczyk D, Jakubowska A, et al. Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. J Clin Oncol. 2011;29:3747-52. This study demonstrates that the risk of breast cancer in women carrying the common CHEK2 1100delC mutation is higher in women with familial breast cancer.
103. Schutte M, Seal S, Barfoot R, et al. Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility. Am J Hum Genet. 2003;72:1023-8. (Pubitemid 36403321)
104. Dong X, Wang L, Taniguchi K, et al. Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet. 2003;72:270-80. (Pubitemid 36194238)
105. Weischer M, Heerfordt IM, Bojesen SE, et al. CHEK2*1100delC and risk of malignant melanoma: Danish and German studies and meta-analysis. J Invest Dermatol. 2012;132:299-303.
106. Xiang HP, Geng XP, Ge WW, Li H. Meta-analysis of CHEK2 1100delC variant and colorectal cancer susceptibility. Eur J Cancer. 2011;47:2546-51.
107. Cybulski C, Gorski B, Huzarski T, et al. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet. 2004;75:1131-5. (Pubitemid 39532081)
108. Domchek SM, Bradbury A, Garber JE, et al. Multiplex genetic testing for cancer susceptibility: out on the high wire without a net? J Clin Oncol. 2013;31:1267-70.
109. Xia B, Sheng Q, Nakanishi K, et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell. 2006;22:719-29.
110. • Casadei S, Norquist BM, Walsh T, et al. Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. Cancer Res. 2011;71:2222-9. This study describes the mutational spectrum and cancer risks in families with PALB2 mutations.
111. Erkko H, Xia B, Nikkila J, et al. A recurrent mutation in PALB2 in Finnish cancer families. Nature. 2007;446:316-9. (Pubitemid 46426155)
112. Foulkes WD, Ghadirian P, Akbari MR, et al. Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women. Breast Cancer Res. 2007;9:R83.
113. Reid S, Schindler D, Hanenberg H, et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet. 2007;39:162-4. (Pubitemid 46184345)
114. Xia B, Dorsman JC, Ameziane N, et al. Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet. 2007;39:159-61. (Pubitemid 46184344)
115. Jones S, Hruban RH, Kamiyama M, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science. 2009;324:217.
116. Hofstatter EW, Domchek SM, Miron A, et al. PALB2 mutations in familial breast and pancreatic cancer. Fam Cancer. 2011;10:225-31.
117. Savitsky K, Sfez S, Tagle DA, et al. The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species. Hum Mol Genet. 1995;4:2025-32.
118. Morrell D, Cromartie E, Swift M. Mortality and cancer incidence in 263 patients with ataxia-telangiectasia. J Natl Cancer Inst. 1986;77:89-92. (Pubitemid 16077187)
119. Bhatti S, Kozlov S, Farooqi AA, et al. ATM protein kinase: the linchpin of cellular defenses to stress. Cell Mol Life Sci. 2011;68:2977-3006.
120. Athma P, Rappaport R, Swift M. Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet. 1996;92:130-4. (Pubitemid 26427675)
121. FitzGerald MG, Bean JM, Hegde SR, et al. Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat Genet. 1997;15:307-10. (Pubitemid 27098729)
122. Renwick A, Thompson D, Seal S, et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet. 2006;38:873-5. (Pubitemid 44141653)
123. Thompson D, Duedal S, Kirner J, et al. Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst. 2005;97:813-22. (Pubitemid 40909124)
124. Roberts NJ, Jiao Y, Yu J, et al. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov. 2012;2:41-6.
125. Fletcher O, Johnson N, dos Santos SI, et al. Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls. Cancer Epidemiol Biomarkers Prev. 2010;19:2143-51.
126. • Tavtigian SV, Oefner PJ, Babikyan D, et al. Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer. Am J Hum Genet. 2009;85:427-46. This article importantly describes the types of missense mutations, which may be associated with ataxia telangiectasia when homozygous and breast cancer when heterozgyous.
127. Feigin RD, Vietti TJ, Wyatt RG, et al. Ataxia telangiectasia with granulocytopenia. J Pediatr. 1970;77:431-8.
128. Briani C, Schlotter M, Lichter P, Kalla C. Development of a mantle cell lymphoma in an ATM heterozygous woman after occupational exposure to ionising radiation and somatic mutation of the second allele. Leuk Res. 2006;30:1193-6. (Pubitemid 44037076)
129. Bernstein JL, Haile RW, Stovall M, et al. Radiation exposure, the ATM Gene, and contralateral breast cancer in the women's environmental cancer and radiation epidemiology study. J Natl Cancer Inst. 2010;102:475-83.
130. Meyer A, John E, Dork T, et al. Breast cancer in female carriers of ATM gene alterations: outcome of adjuvant radiotherapy. Radiother Oncol. 2004;72:319-23. (Pubitemid 39265386)
131. Bremer M, Klopper K, Yamini P, et al. Clinical radiosensitivity in breast cancer patients carrying pathogenic ATM gene mutations: no observation of increased radiation-induced acute or late effects. Radiother Oncol. 2003;69:155-60. (Pubitemid 37485874)
132. Levitus M, Waisfisz Q, Godthelp BC, et al. The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J. Nat Genet. 2005;37:934-5. (Pubitemid 43086148)
133. Levran O, Attwooll C, Henry RT, et al. The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia. Nat Genet. 2005;37:931-3. (Pubitemid 43086147)
134. Rafnar T, Gudbjartsson DF, Sulem P, et al. Mutations in BRIP1 confer high risk of ovarian cancer. Nat Genet. 2011;43:1104-7.
135. Bartkova J, Tommiska J, Oplustilova L, et al. Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene. Mol Oncol. 2008;2:296-316.
136. Heikkinen K, Rapakko K, Karppinen SM, et al. RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability. Carcinogenesis. 2006;27:1593-9. (Pubitemid 44288048)
137. Tommiska J, Seal S, Renwick A, et al. Evaluation of RAD50 in familial breast cancer predisposition. Int J Cancer. 2006;118:2911-6. (Pubitemid 43673377)
138. Stewart GS, Maser RS, Stankovic T, et al. The DNA double-strand break repair gene hMRE11 is mutated in individuals with an ataxia-telangiectasia-like disorder. Cell. 1999;99:577-87. (Pubitemid 30004634)
139. Varon R, Vissinga C, Platzer M, et al. Nibrin, a novel DNA double-strand break repair protein, is mutated in Nijmegen breakage syndrome. Cell. 1998;93:467-76. (Pubitemid 28232090)
140. Waltes R, Kalb R, Gatei M, et al. Human RAD50 deficiency in a Nijmegen breakage syndrome-like disorder. Am J Hum Genet. 2009;84:605-16.
141. Meindl A, Hellebrand H, Wiek C, et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet. 2010;42:410-4.
142. Loveday C, Turnbull C, Ramsay E, et al. Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet. 2011;43:879-82.
143. Thompson ER, Boyle SE, Johnson J, et al. Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients. Hum Mutat. 2012;33:95-9.
144. Thompson ER, Rowley SM, Sawyer S, et al. Analysis of RAD51D in ovarian cancer patients and families with a history of ovarian or breast cancer. PLoS One. 2013;8:e54772.
145. Vaz F, Hanenberg H, Schuster B, et al. Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet. 2010;42:406-9.
146. •• Robson ME, Storm CD, Weitzel J, et al. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol. 2010;28:893-901. This article describes the most recent ASCO guidelines regarding germline testing for cancer susceptibility.
147. Shannon KM, Chittenden A. Genetic testing by cancer site: breast. Cancer J. 2012;18:310-9.
148. Shendure J, Aiden EL. The expanding scope of DNA sequencing. Nat Biotechnol. 2012;30:1084-94.
149. Biesecker LG, Burke W, Kohane I, et al. Next-generation sequencing in the clinic: are we ready? Nat Rev Genet. 2012;13:818-24.
150. Kohlmann A, Grossmann V, Haferlach T. Integration of next-generation sequencing into clinical practice: are we there yet? Semin Oncol. 2012;39:26-36.
151. Gopie JP, Mureau MA, Seynaeve C, et al. Body image issues after bilateral prophylactic mastectomy with breast reconstruction in healthy women at risk for hereditary breast cancer. Fam Cancer. 2012;[Epub ahead of print]
152. Gahm J, Wickman M, Brandberg Y. Bilateral prophylactic mastectomy in women with inherited risk of breast cancer-prevalence of pain and discomfort, impact on sexuality, quality of life and feelings of regret 2 years after surgery. Breast. 2010;19:462-9.
153. Zendejas B, Moriarty JP, O'Byrne J, et al. Cost-effectiveness of contralateral prophylactic mastectomy vs routine surveillance in patients with unilateral breast cancer. J Clin Oncol. 2011;29:2993-3000.
154. Easton DF, Deffenbaugh AM, Pruss D, et al. A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet. 2007;81:873-83. (Pubitemid 47580242)
155. Guidugli L, Pankratz VS, Singh N, et al. A classification model for BRCA2 DNA binding domain missense variants based on homology directed repair activity. Cancer Res. 2013;73:265-75.